For the best experience, please enable JavaScript in your browser settings. Wearing your protective style for too long actually damages your hair (Shutterstock ...

Researchers examined the impact of baricitinib withdrawal and retreatment on hair regrowth in patients with severe alopecia areata. Although baricitinib has demonstrated efficacy for treating patients ...

This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areata, a population often underrepresented in clinical trials New data show ...

Baricitinib showed significant hair regrowth in adolescents with severe alopecia areata, with 71% achieving successful scalp regrowth at 52 weeks on a 4 mg dose. The study highlighted the importance ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for LITFULO™ (ritlecitinib) to treat adults and adolescents 12 ...

SAN FRANCISCO, July 29, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ...

Alopecia universalis (AU) is a rare autoimmune condition that involves complete loss of hair on your face, scalp, and body. The earlier you seek treatment, the better your chances of maintaining your ...

Hair loss caused by alopecia areata now has a new FDA-approved treatment, a third-in-class drug from Sun Pharmaceutical Industries that will compete against commercialized medicines from Eli Lilly and ...